Biotech | October 18, 2021
U.S. FDA advisory committee recommends J&J booster dose
U.S. FDA to decide whether to authorize a booster dose in the coming days
U.S. FDA to decide whether to authorize a booster dose in the coming days
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
The vaccine was 85 percent effective in preventing severe disease across all regions.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)